About 10–15% of breast cancers over-express the HER2/erb2/neu receptor protein, a receptor tyrosine kinase that signals cellular proliferation and patients with HER2+ tumors used to have one of the worst prognoses until the advent of anti-HER2 targeted therapies (4). Here, ERBB2 is linked to breast cancer.